Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
THRIVE
A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)
1 other identifier
observational
1,500
1 country
32
Brief Summary
The purpose of this prospective observational study is to collect data from participants who have recently had an allogenic Stem Cell Transplant(alloSCT) and are at risk of Chronic Graft Versus Host Disease(cGVHD)
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2023
Longer than P75 for all trials
32 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 5, 2023
CompletedFirst Posted
Study publicly available on registry
June 26, 2023
CompletedStudy Start
First participant enrolled
August 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 15, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
October 15, 2027
March 24, 2026
March 1, 2026
4.2 years
May 5, 2023
March 20, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Overall Burden of cGVHD diagnosis and severity
36 months
Secondary Outcomes (2)
To describe personal and healthcare resources associated with the management of cGVHD
36 months
To describe changes in the proteomic, cytologic and molecular profile in blood, serum and saliva cGVHD
Up to 36 months
Study Arms (1)
At risk for GVHD
Equal or Greater than 18 years old post alloSCT
Interventions
Eligibility Criteria
Participants greater than or equal to 18 years of age who have had Allogenic SCT 90 to 180 days prior to enrollment
You may qualify if:
- Age ≥ 18 years inclusive at the time of signing the ICF
- Allogeneic SCT 90 to 180 days prior to enrollment
- Able to comprehend and willing to provide informed consent
- Willing and able to complete participant-assessment questionnaires either alone or with minimal assistance from a caregiver and/or trained site personnel
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (32)
University of Alabama Birmingham
Birmingham, Alabama, 35294, United States
Mayo Clinic Arizona
Phoenix, Arizona, 85054, United States
City of Hope
Duarte, California, 91010, United States
USC Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
University of Colorado
Aurora, Colorado, 80309, United States
Mayo Clinic Jacksonville
Jacksonville, Florida, 32224, United States
AdventHealth Orlando
Orlando, Florida, 32803, United States
Moffit Cancer Center
Orlando, Florida, 33612, United States
Emory University
Atlanta, Georgia, 30322, United States
Georgia Cancer Center
Augusta, Georgia, 30912, United States
Northwestern University
Chicago, Illinois, 60611, United States
Rush University Medical Group
Chicago, Illinois, 60612, United States
The University of Chicago
Chicago, Illinois, 60637, United States
Loyola University Medical Center
Maywood, Illinois, 60153, United States
The University of Kansas Clinical Research Center
Fairway, Kansas, 66205, United States
Tulane Cancer Center
New Orleans, Louisiana, 70112, United States
University of Maryland Medical Center
Baltimore, Maryland, 21201, United States
Massachusetts Cancer Research Center
Boston, Massachusetts, 02114, United States
Corewell Health
Grand Rapids, Michigan, 49503, United States
Mayo Clinic Rochester
Rochester, Minnesota, 55905, United States
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08602, United States
Memorial Sloan Kettering Cancer Center
New York, New York, 10021, United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27514, United States
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
The Ohio State University
Columbus, Ohio, 43201, United States
Oregon Health Sciences University
Portland, Oregon, 97239, United States
Geisinger Health Systems
Danville, Pennsylvania, 17822, United States
Vanderbilt University Medical Center
Nashville, Tennessee, 37212, United States
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Dallas, Texas, 75246, United States
University of Utah, Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
Related Links
Biospecimen
blood and saliva
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 5, 2023
First Posted
June 26, 2023
Study Start
August 1, 2023
Primary Completion (Estimated)
October 15, 2027
Study Completion (Estimated)
October 15, 2027
Last Updated
March 24, 2026
Record last verified: 2026-03
Data Sharing
- IPD Sharing
- Will not share